Seelos Therapeutics, Inc.

Seelos Therapeutics, Inc.verified

SEEL

Price:

$0.1906

Market Cap:

$1.33M

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients ...[Read more]

Industry

Biotechnology

IPO Date

1999-04-19

Stock Exchange

NASDAQ

Ticker

SEEL

The Enterprise Value as of September 2024 (TTM) for Seelos Therapeutics, Inc. (SEEL) is 11.19M

According to Seelos Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 11.19M. This represents a change of -89.29% compared to the average of 104.49M of the last 4 quarters.

Seelos Therapeutics, Inc. (SEEL) Historical Enterprise Value (quarterly & annually)

How has SEEL Enterprise Value performed in the past?

The mean historical Enterprise Value of Seelos Therapeutics, Inc. over the last ten years is 1.38B. The current 11.19M Enterprise Value has changed -18.96% with respect to the historical average. Over the past ten years (40 quarters), SEEL's Enterprise Value was at its highest in in the March 2015 quarter at 21.41B. The Enterprise Value was at its lowest in in the June 2024 quarter at 11.41M.

Quarterly (TTM)
Annual

Average

1.38B

Median

480.35M

Minimum

65.33M

Maximum

9.52B

Seelos Therapeutics, Inc. (SEEL) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Seelos Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 169.89%

Maximum Annual Enterprise Value = 9.52B

Minimum Annual Increase = -95.80%

Minimum Annual Enterprise Value = 65.33M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202365.33M-88.79%
2022582.81M-48.27%
20211.13B101.01%
2020560.48M169.89%
2019207.67M47.13%
2018141.14M-16.43%
2017168.89M-83.74%
20161.04B159.53%
2015400.23M-95.80%
20149.52B-56.56%

Seelos Therapeutics, Inc. (SEEL) Average Enterprise Value

How has SEEL Enterprise Value performed in the past?

The current Enterprise Value of Seelos Therapeutics, Inc. (SEEL) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

591.58M

5-year avg

508.58M

10-year avg

1.38B

Seelos Therapeutics, Inc. (SEEL) Enterprise Value vs. Peers

How is SEEL’s Enterprise Value compared to its peers?

Seelos Therapeutics, Inc.’s Enterprise Value is less than Atai Life Sciences N.V. (193.00M), less than Mind Medicine (MindMed) Inc. (296.54M), less than GH Research PLC (333.50M), greater than Freeline Therapeutics Holdings plc (2.82M), less than Cybin Inc. (20.34M), greater than Awakn Life Sciences Corp. (3.57M), greater than Pulmatrix, Inc. (-6324963.00), less than Capricor Therapeutics, Inc. (137.70M), less than Akari Therapeutics, Plc (38.48M), greater than Diffusion Pharmaceuticals Inc. (-1447403.00), less than Soleno Therapeutics, Inc. (1.99B), less than Eliem Therapeutics, Inc. (330.21M), less than Opthea Limited (539.83M), greater than Molecular Partners AG (-9807180.92), less than Edgewise Therapeutics, Inc. (1.53B), less than iTeos Therapeutics, Inc. (189.03M), greater than TRACON Pharmaceuticals, Inc. (-6065546.00), greater than Histogen Inc. (-3643892.00), less than Entera Bio Ltd. (62.85M), less than Tempest Therapeutics, Inc. (23.29M), greater than Better Therapeutics, Inc. (7.71M),

Build a custom stock screener for Seelos Therapeutics, Inc. (SEEL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Seelos Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Seelos Therapeutics, Inc. (SEEL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Seelos Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Seelos Therapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Seelos Therapeutics, Inc. (SEEL)?

What is the 3-year average Enterprise Value for Seelos Therapeutics, Inc. (SEEL)?

What is the 5-year average Enterprise Value for Seelos Therapeutics, Inc. (SEEL)?

How does the current Enterprise Value for Seelos Therapeutics, Inc. (SEEL) compare to its historical average?